Search PubMed⌕ Search

Biomedical subjects

H Schultz

Publications and source records attributed to H Schultz.

At least 91 records · Page 5Linked to original sources
PubMed1980

[Communicative performance using hearing aids (author's transl)].

By means of a questionnaire the utilization of hearing aids has been investigated in 550 patients who had received their aids in the way being typical for the Federal Republic of Germany, i.e. after being prescribed by the ENT-specialist the hearing aid is fitted by the hearing aid acoustician. Additionally the study aimed to analyze relevant factors influencing the use of hearing aids. 45% of the patients used their aids always, 52% regularly (on special occasions) and 3,1% never. The most common complaints of patients refusing their hearing aid were disturbing noise and unsatisfactory understanding. A relatively better utilization of hearing aids--as compared with the average use of the whole group--was found in children, in patients with a hearing loss of a higher degree or with a conductive hearing loss and in patients wearing aids on both ears or aids having a PC-circuit or a so-called "dynamic compression". Relatively lower utilization was seen in patients being older than 60 years, in patients wearing the hearing aid on the worse ear and in workmen. Further factors related to less regular use were: mild hearing loss and high-tone deafness, bone conductive earphone, eyeglass hearing aid and AVC-circuit. There was no correlation between the hearing aid use and the monosyllable discrimination score.

Adolescent↗
PubMed1980

[The dignity of the patient: a legal problem?].

Rules of medical ethic bid since the times of antiquity to respect the patients dignity. Today to respect the dignity of any man is a general legal rule. In the same way other rules of the traditional medical ethic became legal norms as for instance the command forbidding to do harm to someone. The law intends to limit the possibilities to exercise power. Therefore it does not compete to the doctor alone to decide that a medical treatment has to be applied. The legal base of a medical treatment lies in the consent of the patient who has been duly cleared up on his state, the necessary treatment and its risks. If it has to be decided if a doctor has given the right treatment in a special case it does not suffice to consult the general rules of the law; the circumstances of the case have to be considered as well. The doctor has to decide, according to the actual medical knowledge and the rules of his professional art what the appropriate proceeding is. Legal and medical considerations are closely connected if one judges a doctor handling a special case. If the patient consents, the doctor is not obliged to treat him, but he is entitled to do it, cases of emergency excepted. If and in what way he treats the patient has to be decided by the doctor according to medical criterias. If a patient, sound of mind, who is suffering heavily by an incurable illness asks the doctor to restrain treatment to alleviating the pains and to the absolute cares to preserve life, the doctor is bound by his patient's wish. In analogy the legal construct of "conducting business without mandate" allows the doctor to proceed in the same way if the patient who lost consciousness is not able to decide upon the treatment and whose death is inevitable and imminent if this is the only wise to respect the dignity of the patient.

Ethics, Medical↗
PubMed1979

[Transfer factor (TF) treatment of patients with HBs-Ag-positive chronic active hepatitis. A prospective, controlled study (author's transl)].

It is a clinically and experimentally well supported working hypothesis that infection with hepatitis B virus may result in chronic active hepatitis in patients with suspected immune deficiencies. On this basis, a pilot study was performed in order to evaluate the effect of "specific" transfer factor (TF) in the treatment of HBS-Ag-positive chronic active hepatitis. From the leukocytes of 500 ml venous blood each of 40 volunteers that had completely recovered from acute virus hepatitis B within the last 6 months, a unique TF pool (40 units of TF) was prepared according to the method of Lawrence. Preexaminations indicated that this preparation was able to enhance cellular immune reactions in vitro. Thirteen patients with HBS-antigenemia and chronic active hepatitis (i.e., two liver biopsies within the last 6 or more months with the histological criteria of chronic aggressive hepatitis according to de Groote, elevated serum levels of bilirubin, alkaline phosphatase, transaminase activities, and/or gamma-globulines) were randomized: Seven received s.c. injections of two units of TF each on days 1 and 15, the other six saline. Conversion of skin reactions to some ubiquitous antigens occurred in the TF group, but no significant and constant drop of HBS-Ag serum titers was observed. Although some of the biochemical parameters seemed to ameliorate in the TF group, the differences versus the control group did not prove to be significant within the limited number of patients under observation. The in vitro reactivity of patients' lymphocytes to HBS-Ag, tested by means of the 3H-thymidine uptake, was never found enhanced after TF application. In the used doses, "specific" TF was not effective in the treatment of HBS-Ag-positive chronic active hepatitis; unfavorable side-effects were not observed.

Adult↗
PubMed1979

[Circulating immune complexes in bronchogenic carcinoma: relation to extent of disease and to therapy (author's transl)].

In sera of 72 patients with lung cancer, 20 patients with various benign lung diseases and 34 age matched controls circulating immune complexes were determined by column chromatography on Sepharose 6 B and subsequent testing of the eluate for macromolecular IgG as well as by inhibition of radiolabelled C1q binding to sensitized sheep erythrocytes. Whereas in both control and benign lung disease-sera complexes could be detected in less than 5%, sera of lung cancer patients showed macromolecular IgG in 83% and C1q reactive material in 53% at the time of diagnosis. Patients with metastases exhibited a significantly higher percentage of positive reactions than those without metastases (macromolecular IgG 93%/68%, C1q 71%/28%). The size of the complexes increased with the extent of disease. So far, no signficiant changes in circulating immune complexes could be demonstrated id pretherapeutic values were compared with those after X-ray-, chemo- or immunotherapy with one exception, which is an increase of C1q reactive material after radiotherapy.

Antigen-Antibody Complex↗
PubMed1979

Nephroblastoma. Results and complications of treatment.

Treatment results in 31 patients with nephroblastoma are reported. Survival seemed superior in patients who received Actinomycin-D in addition to surgery and postoperative irradiation. Twelve long-term surviving children were evaluated for side-effects of the treatment. Although inhibition of growth and other abnormalities occurred in most survivors, little permanent disability and dysfunction appears to have resulted from the treatment.

Adipose Tissue↗
PubMed1979

Serum lipoprotein inhibitors of granulopoiesis in human bone marrow cultures.

Ammonium sulphate fractionation of human serum showed that two fractions contained an inhibitor of cluster and colony formation in agar cultures of human bone marrow cells. Further investigations demonstrated this inhibition to be caused by lipoproteins. When freshly prepared, only light density lipoproteins (LDL) were found to be inhibitory. During storage, very light density lipoproteins (VLDL) acquired inhibitory activity, while high density lipoproteins (HDL) did not show any inhibition of human bone marrow cultures. The possibility of toxic degradation of lipoproteins as an explanation for the inhibition was investigated by preincubation of human marrow cells with lipoproteins for 6 hours (37 degrees C) after storage of the lipoproteins under nitrogen (4 degrees C) for various intervals up to 48 days. Preincubation was found to be non-toxic (viable cell counts) and without colony/cluster-reducing ability for incubated marrow cells compared to controls. Addition of lipoproteins to mouse marrow cells and Ehrlich ascites tumour cells resulted in no change in colony formation by Ehrlich cells, whereas mouse marrow cells were inhibited, but to a lesser degree than human marrow cells.

Bone Marrow Cells↗
PubMed1978

Serum alpha-fetoprotein and human chorionic gonadotropin as markers for the effect of postoperative radiation therapy and/or chemotherapy in testicular cancer.

Human alpha1-fetoprotein (AFP) and chroiongonadotropin (hCG) have been studied in 67 patients with malignant germ cell neoplasia of the testis admitted to the Radium Centre, Aarhus Municipal Hospital within an 18 month period. In 34 patients with nonseminoma, AFP was elevated in 35% of cases and hCG in 38% of cases. Nonseminoma patients who presented with or developed distant metastases showed a significantly higher incidence of elevated tumor markers than patients with local or regional disease. In patients with distant metastases monitoring of AFP and/or hCG was a most sensitive and reliable indicator of disease activity. In the management of such patients these tests are as important as clinical and x-ray examinations.

Antineoplastic Agents↗
PubMed1978

Trigeminal neuralgia in aqueduct stenosis.

Trigeminal neuralgia was the presenting symptom in two patients with aqueduct stenosis, hydrocephalus, and raised intracranial pressure. Treatment of the hydrocephalus resulted in the remission of pain in both patients.

Adult↗
PubMed1975

Human infestation by Ophionyssus natricis snake mite.

A family presented with a papular vesiculo-bullous eruption of the skin, found to be caused by the snake mite, Ophionyssus natricis (Cervais, 1844). A pet python was the primary host. Treatment of the animal and its environment led to clearance of the human skin lesions.

Adult↗
PubMed1975

Assessment of verapamil in the treatment of angina pectoris.

A brief review is given of the pharmacological data of verapamil, which chemically shows a certain similarity to papaverine. The effect of the drug (80 mg) 3 times daily, on angina pectoris, as compared with placebo, was evaluated in a double-blind cross-over therapeutic trial with 4-wk periods in 47 patients. The incidence of attacks and the nitroglycerine consumption decreased in the second fortnight of the verapamil period by approximately 25% compared with the placebo period. An ergometer test showed a prolongation of the exerice time of 20%. The mean blood pressure and the heart rate fell under verapamil treatment if the patients had values which were relatively high in the placebo period. The increase in heart rate during exercise from two different resting levels showed a tendency to become more pronounced under treatment with verapamil than under placebo. The length of the P-Q intervals were not affected by verapamil. The mechanism of action in angina pectoris is discussed, but it is concluded that it is still not possible to explain it. Twelve Danish medical departments took part in the trial.

Aged↗